Quick Answer
PUMA BIOTECHNOLOGY, INC. reported Cash and Equivalents of $29.64 million for fiscal year 2025.
PUMA BIOTECHNOLOGY, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $29.64M | -57.2% |
| 2024 | $69.22M | -18.2% |
| 2023 | $84.58M | +11.0% |
| 2022 | $76.20M | +20.7% |
| 2021 | $63.13M | -26.0% |
| 2020 | $85.29M | +42.1% |
| 2019 | $60.04M | -44.6% |
| 2018 | $108.42M | +32.7% |
| 2017 | $81.70M | -58.0% |
| 2016 | $194.49M | +516.1% |
| 2015 | $31.57M | -18.1% |
| 2014 | $38.54M | -10.5% |
| 2013 | $43.04M | -68.7% |
| 2012 | $137.41M | +157.4% |
| 2011 | $53.38M | — |
| 2010 | $0.00 | — |
| 2010 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $53.52M | -20.4% | -2.1% |
| June 30, 2025 | $54.66M | -18.6% | -13.3% |
| March 31, 2025 | $63.03M | -17.9% | -8.9% |
| December 31, 2024 | $69.22M | -18.2% | +2.9% |
| September 30, 2024 | $67.26M | -17.8% | +0.2% |
| June 30, 2024 | $67.15M | +11.9% | -12.5% |
| March 31, 2024 | $76.75M | +25.0% | -9.3% |
| December 31, 2023 | $84.58M | +11.0% | +3.4% |
- PUMA BIOTECHNOLOGY, INC. showed a decrease of -57.2% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from PUMA BIOTECHNOLOGY, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: